PL400149A1 - Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9 - Google Patents

Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9

Info

Publication number
PL400149A1
PL400149A1 PL400149A PL40014912A PL400149A1 PL 400149 A1 PL400149 A1 PL 400149A1 PL 400149 A PL400149 A PL 400149A PL 40014912 A PL40014912 A PL 40014912A PL 400149 A1 PL400149 A1 PL 400149A1
Authority
PL
Poland
Prior art keywords
alkyl
group
straight
pyrazolo
pyrimidine
Prior art date
Application number
PL400149A
Other languages
English (en)
Inventor
Rafal Moszczynski-Petkowski
Łukasz Bojarski
Filip Stefaniak
Maciej Wieczorek
Krzysztof Dubiel
Monika Lamparska-Przybysz
Original Assignee
Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL400149A priority Critical patent/PL400149A1/pl
Priority to PCT/IB2013/056086 priority patent/WO2014016789A1/en
Publication of PL400149A1 publication Critical patent/PL400149A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zwiazki przedstawione wzorem ogólnym (I), w którym R1 jest wybrany z grupy skladajacej sie z fenylu niepodstawionego lub podstawionego przez 1 do 3 podstawników wybranych z F, Cl, Br, J, CN, -O-C1-C3-alkilu, fluorowanego -O-C1-C3-alkilu, -(CH2)mOH i 5-czlonowego ugrupowania heterocyklicznego majacego 1 lub 2 heteroatomy wybrane z N, O i S; i 6- lub 10-czlonowego heteroarylu, majacego 1 do 3 heteroatomów wybranych niezaleznie z O, N i S; R2 i R3 oznaczaja niezaleznie od siebie atom H lub alkil C1-C3 o lancuchu prostym lub rozgalezionym; R4 jest wybrany z grupy skladajacej sie z 4- do 6-czlonowego cykloalkilu, w którym jeden z atomów wegla pierscienia moze byc zastapiony przez atom O; i alkilu C1 do C4 o lancuchu prostym lub rozgalezionym; Q oznacza wiazanie lub grupe C1-C3-alkilenowa, która moze byc ewentualnie podstawiona przed jedna do trzech grup C1-C3-alkilowych; X jest wybrany z grupy skladajacej sie z O, NR5, i S(O)p; R5 oznacza atom H lub alkil C1-C3; m oznacza liczbe 1, 2 lub 3; p oznacza liczbe 0, 1 lub 2; oraz ich dopuszczalne farmaceutycznie sole, sa inhibitorami PDE9 i moga znalezc zastosowanie w leczeniu zaburzen funkcji poznawczej i chorób neurozwyrodnieniowych.
PL400149A 2012-07-26 2012-07-26 Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9 PL400149A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL400149A PL400149A1 (pl) 2012-07-26 2012-07-26 Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9
PCT/IB2013/056086 WO2014016789A1 (en) 2012-07-26 2013-07-24 Pyrazolo[3,4-d]pyrimidin-4(5h)-one derivatives as pde9 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL400149A PL400149A1 (pl) 2012-07-26 2012-07-26 Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9

Publications (1)

Publication Number Publication Date
PL400149A1 true PL400149A1 (pl) 2014-02-03

Family

ID=49301560

Family Applications (1)

Application Number Title Priority Date Filing Date
PL400149A PL400149A1 (pl) 2012-07-26 2012-07-26 Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9

Country Status (2)

Country Link
PL (1) PL400149A1 (pl)
WO (1) WO2014016789A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
KR20200068996A (ko) * 2018-12-06 2020-06-16 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EA201100446A1 (ru) 2008-09-08 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолопиримидины и их применение для лечения нарушений цнс
MY156377A (en) 2009-03-31 2016-02-15 Boehringer Ingelheim Int 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201118099A (en) 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica

Also Published As

Publication number Publication date
WO2014016789A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
PE20200388A1 (es) Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock
EA201591000A1 (ru) Пирролобензодиазепины
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
EA200970379A1 (ru) Бициклические гетероароматические соединения
TN2013000394A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
RS54776B1 (sr) Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
RS53153B (en) ANTAGONISTS OF HYSTAMINE -3 RECEPTORS
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
MX2011009034A (es) Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
EA201590020A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201590023A1 (ru) Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
NZ723502A (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
GEP201606507B (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)